On August 3, 2026, the California Supreme Court issued its decision in the closely watched Gilead Tenofovir Cases, No. S283862, — Cal.5th —, 2026 WL 2223748 (Cal. Aug. 3, 2026), rejecting the so-called “duty to innovate.” The court held, in a 6-1 decision, that “a drug manufacturer has no duty of care when deciding whether and when to develop and commercialize an allegedly safer alternative drug” to replace an admittedly nondefective drug. The decision is a significant victory for pharmaceutical manufacturers and carries substantial implications for product liability litigation across industries.
Background
The case arose from a Judicial Counsel Coordination Proceeding comprising more than 30,000 plaintiffs — HIV patients who took Gilead’s tenofovir disoproxil fumarate (TDF). Plaintiffs did not claim TDF was defective; it is undisputedly a life-saving medication. Instead, they alleged Gilead unreasonably delayed bringing an alternative medication, tenofovir alafenamide (TAF), to market, depriving them of a purportedly safer option and allegedly causing kidney, bone, or tooth injuries.
The trial court denied Gilead’s summary judgment motion on the negligence claim, and the court of appeal affirmed, holding that a manufacturer’s duty of care could extend beyond marketing a nondefective product. See Gilead Tenofovir Cases, 98 Cal. App. 5th 911 (2024). The California Supreme Court reversed.
The Court’s Reasoning
The court expressed “substantial doubt” that California law recognizes a negligence duty requiring drug manufacturers to act reasonably in development and commercialization decisions apart from their established duty to market products free from manufacturing, design, and warning defects. But even assuming such a duty could exist, the court held that the Rowland v. Christian, 69 Cal.2d 108 (1968), foreseeability, and public policy factors warranted an exception.
On foreseeability, the court reasoned that a manufacturer cannot determine a drug’s safety and efficacy during early-stage clinical testing, making harm from development delays unforeseeable. It also found the causal chain between purported development delays and a patient’s injury attenuated, as it depends on uncertain scientific outcomes and independent decisions by regulators, physicians, and patients.
On public policy, the court held that moral blame is not meaningfully implicated given the morally neutral reasons that may underlie development decisions. The court further found that imposing such a duty would risk distorting research priorities, discouraging innovation, and inviting hindsight-based second-guessing of complex scientific judgments — while imposing substantial burdens on manufacturers.
The court summarized its decision as follows:
What today’s decision declines to do is recognize, for the first time anywhere, sweeping liability for injuries caused by a concededly nondefective drug because the manufacturer allegedly failed to make a different drug available sooner. Imposing such liability would create substantial burdens and would risk adverse consequences for pharmaceutical innovation, public health, and patient safety. For these reasons, we conclude that drug manufacturers do not owe a duty of care to users of a nondefective drug when making decisions about whether and when to commercialize an allegedly safer alternative drug.
The court reversed the court of appeal and directed the trial court to enter summary judgment for Gilead on all causes of action. Chief Justice Guerrero concurred separately, arguing the defect requirement itself forecloses plaintiffs’ theory without reaching the Rowland analysis. Justice Evans dissented.
Broader Implications
Although the court limited its holding to pharmaceutical manufacturers, it expressly recognized that plaintiffs’ theory has no logical stopping point. The court observed that manufacturers in any industry could face liability for development decisions — even when the product is nondefective — and cautioned that manufacturers “might avoid researching or testing potential safety improvements altogether for fear that preliminary findings might later be used to allege negligence.”
Key takeaways for product liability practitioners:
- The decision reinforces the product defect requirement as the cornerstone of California product liability law.
- Manufacturers of medical devices, automobiles, and other regulated products can invoke this decision to resist “duty to innovate” theories.
- The court’s Rowland analysis provides a detailed framework for arguing that complex R&D and commercialization decisions should not be second-guessed through tort litigation.
- Plaintiffs pursuing innovation-delay theories will need to ground their claims in traditional defect-based frameworks to survive a duty challenge.
The material contained in this communication is informational, general in nature and does not constitute legal advice. The material contained in this communication should not be relied upon or used without consulting a lawyer to consider your specific circumstances. This communication was published on the date specified and may not include any changes in the topics, laws, rules or regulations covered. Receipt of this communication does not establish an attorney-client relationship. In some jurisdictions, this communication may be considered attorney advertising.
